@article{e2de7855306b4613b972e68d6c45c0eb,
title = "Balancing patient value and payer cost in hematologic malignancies: can it be done?",
keywords = "Cost-effective, leukemia, lymphoma, multiple myeloma, pharmacogenomics",
author = "Allen, {Pamela B.} and Flowers, {Christopher R.}",
note = "Funding Information: CR Flowers discloses being a Consultant: Abbvie, Bayer, Celgene (unpaid), Genentech/Roche (unpaid), Gilead, OptumRx, Spectrum. Research Funding for this Work: Burroughs Wellcome Fund, National Cancer Institute. Other Research Funding: Abbvie, Celgene, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, TG Therapeutics, Eastem Cooperative Oncology Group, National Cancer Institute, V Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. A reviewer on this manuscript has disclosed they are a shareholder of Pharmerit, a HEOR consulting form, which receives funding from a large number of pharmaceutical companies. Funding Information: This paper was funded by the Burroughs Wellcome Fund, NCI K24CA208132.",
year = "2018",
month = mar,
day = "4",
doi = "10.1080/14737167.2018.1444478",
language = "English (US)",
volume = "18",
pages = "123--126",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "2",
}